UK's Cell Medica closes £17 million round
This article was originally published in Scrip
Cell Medica, a UK firm developing immune cell-based therapies, has closed a £17 million funding round which includes a significant contribution from a Texan state fund for cancer research. The firm is to begin new operations in Texas focused on cancer immunotherapy as a result of the funding, which will also finance ongoing immune reconstitution studies in Europe.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.